Clinical Trials

Melanoma

NCT02196181 2026-03-18

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

280 enrolled

Phase 1/2 Active not recruiting

Melanoma

NCT04557956 2026-03-18

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

16 enrolled

Melanoma

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

Melanoma

NCT02645149 2026-02-27

Match Mel

216 enrolled

Melanoma

NCT03501368 2026-02-27

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

27 enrolled

Phase 1 Active not recruiting

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

86 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Phase 3 Active not recruiting

78 enrolled

Melanoma

NCT04666272 2026-02-19

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Active not recruiting

78 enrolled

Phase 3 Active not recruiting

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

267 enrolled 8 charts

Melanoma

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

58 enrolled

Melanoma

NCT03340506 2026-02-03

Dabrafenib and/or Trametinib Rollover Study

Phase 4 Recruiting

100 enrolled

CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT04489433 2025-12-18

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

No longer available

Melanoma

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01972347 2025-12-16

Neo Combi

35 enrolled

Fever, Melanoma

NCT04961619 2025-12-12

LEAD Melanoma

Completed

39 enrolled

Melanoma

NCT05668585 2025-11-21

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

89 enrolled

Melanoma

NCT02967692 2025-09-18

COMBI-i

Phase 3 Terminated

568 enrolled 28 charts

Melanoma, Skin Neoplasms

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Recruiting

270 enrolled

Melanoma, Skin Neoplasms

NCT03551626 2025-04-29

COMBI-APlus

Phase 3 Completed

552 enrolled 12 charts

Fever, Melanoma

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1/2 Not yet recruiting

241 enrolled

DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT05275374 2025-04-10

ENHANCE

221 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT03944356 2025-03-12

Combi-EU

Completed

232 enrolled

Melanoma

NCT03026517 2025-01-23

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

18 enrolled

Melanoma

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

DermatologicOther hematologic neoplasm

27 enrolled 16 charts

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

74 enrolled

Melanoma

NCT02392871 2024-11-27

CombiRT

10 enrolled

Melanoma

NCT04544202 2024-11-12

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

No longer available

Melanoma, Skin Neoplasms

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Terminated

4 enrolled 8 charts

Melanoma

NCT02097225 2024-10-16

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

22 enrolled 21 charts

Melanoma, Neoplasm Metastasis

NCT02143050 2023-11-18

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Phase 1/2 Withdrawn

Melanoma

NCT04059224 2023-09-26

TraMel-WT

45 enrolled

Melanoma

NCT03272464 2023-09-22

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

1 enrolled 6 charts

Melanoma

NCT05299580 2023-09-14

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Phase 2 Withdrawn

870 enrolled 13 charts 1 FDA

Melanoma

NCT01682083 2023-08-30

COMBI-AD

Phase 3 Completed

Melanoma, Neoplasms

NCT02858921 2023-08-30

Neo Trio

Phase 2 Unknown

60 enrolled

Melanoma, Neoplasms

NCT03563729 2023-07-13

MEMBRAINS

Phase 2 Recruiting

80 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04547946 2023-05-30

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Completed

3 enrolled

Melanoma

NCT02130466 2022-08-01

MK-3475-022

184 enrolled 62 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05171374 2022-06-01

RATIONALE

Unknown

500 enrolled

Melanoma

NCT01940809 2022-03-10

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

15 enrolled

Melanoma

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

77 enrolled 43 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Phase 2 Terminated

6 enrolled 3 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02296112 2021-05-28

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

9 enrolled 14 charts

Melanoma

NCT03754179 2021-04-28

COMBI-R2

Phase 1/2 Unknown

63 enrolled

Melanoma

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

31 enrolled

Melanoma, Neoplasms

NCT01584648 2021-02-17

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Phase 3 Completed

423 enrolled 15 charts

Melanoma

NCT03352947 2020-12-08

INTERIM

79 enrolled

Melanoma

NCT03972046 2020-10-19

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Phase 2 Withdrawn

Melanoma, Skin Neoplasms

NCT02410863 2020-10-14

BOTTOM

Phase 2 Terminated

10 enrolled